亞光科技(300123.SZ):控股股東非公開發行可交換公司債將進入換股期
格隆匯 3 月 4日丨亞光科技(300123.SZ)公佈,公司近日接到控股股東湖南太陽鳥控股有限公司(“太陽鳥控股”)關於其非公開發行可交換公司債券進入換股期的通知。
太陽鳥控股於2020年9月8日非公開發行3億元可交換公司債券,本期債券期限為3 年,標的股票為亞光科技A股股票。具體內容詳見公司於2020年9月9日披露的《關於控股股東非公開發行可交換公司債券發行完成的公吿》(公吿編號:2020-093)。根據本期可交債債券募集説明書的約定,本期可交債自2021年3月9日進入換股期,換股期限為2021年3月9日至2023年9月7日,換股價格為20.25元/股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.